Related Experiment Video
Updated: Dec 20, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders
Lars E Larsen1, Mikhaila A Smith2, Deepti Abbey2
1Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Abstract:
Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Tissue Renewal without Stem Cells
However, failure of such a system...

